KCA 098

04/01/1994 - "In addition, in an in vivo experiment, oral administration of KCA-098 (3.0 mg/kg/d) for 16 weeks led to an increase in calcium and phosphorus content as well as an increase in the amount of force required to break the femur from ovariectomized rats, suggesting that it may be useful for the treatment of bone diseases."

08/01/1994 - "In this study, to determine if KCA-098 is therapeutically applicable for the treatment of osteoporosis, we compared the effect of KCA-098 on bone tissues with that of ipriflavone, a drug that is clinically used for the treatment of osteoporosis. "
08/01/1994 - "Therefore, KCA-098 seems to be more potent than ipriflavone in stimulating bone tissue formation and may thus be expected to become a useful agent for the treatment of osteoporosis."

07/01/1994 - "KCA-098 (1 mg/kg), a new benzofuroquinoline derivative that inhibits bone resorption and at the same time stimulates bone mineralization in organ culture, protected against these decreases when given orally for 8 weeks. "
04/01/1994 - "These results show that KCA-098 has the unique effects of inhibiting bone resorption and stimulating bone formation of chick embryo. "
04/01/1994 - "KCA-098 dose-dependently inhibited bone resorption of cultured chick embryonic femora and calvariae. "
03/01/1994 - "Thus KCA-098 is a unique, new inhibitor of bone resorption that has no estrogenic activity."
01/26/1996 - "They did, however, dose-dependently inhibit osteoclast-like cell formation as well as KCA-098 did, indicating that the main action of coumestrol and 17beta-estradiol on bone tissue is the inhibition of bone resorption."